Sigma Planning Corp Has $1.66 Million Stock Holdings in Hims & Hers Health, Inc. $HIMS

Sigma Planning Corp lessened its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 43.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 33,288 shares of the company’s stock after selling 25,586 shares during the quarter. Sigma Planning Corp’s holdings in Hims & Hers Health were worth $1,659,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC increased its stake in shares of Hims & Hers Health by 15.7% during the 1st quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock worth $49,000 after purchasing an additional 227 shares during the last quarter. Bessemer Group Inc. increased its stake in shares of Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after purchasing an additional 312 shares during the last quarter. True Vision MN LLC increased its stake in shares of Hims & Hers Health by 3.6% during the 2nd quarter. True Vision MN LLC now owns 9,376 shares of the company’s stock worth $467,000 after purchasing an additional 328 shares during the last quarter. Allworth Financial LP increased its stake in shares of Hims & Hers Health by 20.0% during the 1st quarter. Allworth Financial LP now owns 2,006 shares of the company’s stock worth $56,000 after purchasing an additional 334 shares during the last quarter. Finally, Signaturefd LLC increased its stake in shares of Hims & Hers Health by 17.7% during the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock worth $76,000 after purchasing an additional 388 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on HIMS shares. Canaccord Genuity Group restated a “buy” rating and set a $68.00 price target on shares of Hims & Hers Health in a research note on Friday, September 12th. Weiss Ratings restated a “hold (c+)” rating on shares of Hims & Hers Health in a research note on Tuesday, October 14th. UBS Group set a $32.00 price target on shares of Hims & Hers Health in a research note on Tuesday. Wall Street Zen lowered shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a research note on Monday, July 28th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Two research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Reduce” and a consensus target price of $45.27.

Insider Activity at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 11,592 shares of the firm’s stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $57.13, for a total transaction of $662,250.96. Following the completion of the transaction, the chief financial officer directly owned 70,232 shares of the company’s stock, valued at approximately $4,012,354.16. This trade represents a 14.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Irene Becklund sold 8,410 shares of the firm’s stock in a transaction dated Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total transaction of $424,705.00. Following the transaction, the insider directly owned 1,418 shares of the company’s stock, valued at $71,609. The trade was a 85.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 712,271 shares of company stock valued at $37,631,985 in the last quarter. Company insiders own 13.71% of the company’s stock.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock opened at $43.75 on Thursday. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 4.46. Hims & Hers Health, Inc. has a fifty-two week low of $19.15 and a fifty-two week high of $72.98. The firm has a fifty day moving average price of $51.35 and a two-hundred day moving average price of $50.79. The company has a market cap of $9.89 billion, a PE ratio of 81.02, a price-to-earnings-growth ratio of 3.09 and a beta of 2.20.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.09. Hims & Hers Health had a net margin of 6.05% and a return on equity of 25.85%. The firm had revenue of $598.98 million during the quarter, compared to the consensus estimate of $578.99 million. During the same period in the prior year, the firm earned $0.32 EPS. The business’s revenue was up 49.2% on a year-over-year basis. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.